**CORRECTION**

**Error in Data in Study of Estimated Cost of Bringing a Drug to Market:** The Original Investigation titled “Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018,” published in the March 3, 2020, issue of *JAMA*, was corrected to update data throughout the article. The data changes originated because of corrections to one of the studies used as a source for clinical trial success rates. In addition to updated data throughout the Original Investigation, accompanying Editorials and Letters necessitated corrections to data. These articles have been corrected online, and a letter of explanation appears in this issue.


**Reporting Error:** The Viewpoint titled “Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability,” published in the May 3, 2022, issue of *JAMA,* misreported that the Health Resources and Services Administration (HRSA) sued 6 pharmaceutical manufacturers when the agency had instead issued enforcement letters. The Viewpoint also should have used the words “interpretive guidance” instead of the word “rules” when talking about the history of court rulings on compliance with the HRSA interpretive guidance. This article has been corrected online.


**Error in Byline:** The Letter to the Editor titled “Review of Antiseizure Medications for Adults With Epilepsy,” published in the August 16, 2022, issue of *JAMA,* included an error in the spelling of the first author’s first name. The author byline has been corrected online and now lists Chaudry Nasir Majeed as the first author.


**Guidelines for Letters**

Letters discussing a recent *JAMA* article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the *JAMA* article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment are required before publication. Letters being considered for publication ordinarily will be sent to the authors of the *JAMA* article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment are required before publication. Letters should be submitted via the *JAMA* online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

**Section Editors:** Jody W. Zylke, MD, Deputy Editor; Kristin Walter, MD, Senior Editor.